Peter G Middleton is an expert in Pulmonology at Westmead Hospital (Australia). As of October 2026, ScienceLeadR ranks Peter G Middleton in the top 1% of experts worldwide for Cystic Fibrosis and Pancreatic Diseases. Peter G Middleton has authored 225 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 789 (community average: 125). How the SLR is computed.

LeadR Profile

Peter G Middleton Westmead Hospital Australia
789 ScienceLeadR Reputation 789
Network Map

Pulmonology

Subspecialties: Nephrology - Immunology - Transplantation

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1990 - 2026

Source: PubMed

Westmead Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 225

Citations

Citations: 10 375 1st author: 42 Last author: 38 Unique author: 9


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Relationship between asthma, obesity and other comorbidities: the Australasian Severe Asthma Registry.
PMID 42823689 — registries, comorbidity, lung, respiratory physiological phenomena, neutrophils, sputum, obesity, sex, asthma
Respir Res20260
Corrigendum to "Mortality Is Increased in Those with a ≥10% Reduction in Spirometry Following Allogeneic Hematopoietic Stem Cell Transplant: A Retrospective 5-Year Follow-up Study from a Single Transplant Service." Transplant Cell Ther. 2025 Jul;31(7):448.e1-448.e9. PMID: 40187496.
PMID 42735895 — cells, mortality, microscopy, electron, scanning transmission, follow-up studies, hematopoietic stem cell transplantation, stem cells, spirometry, transplants, hematopoietic stem cells
Transplant Cell Ther20260
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.
PMID 41837895 — safety, fibrosis, cystic fibrosis, adolescent, genotype, therapeutics
Ann Am Thorac Soc20260
Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.
PMID 42638984 — therapeutics, asthma
J Asthma Allergy20260
Multidisciplinary Cystic Fibrosis Teams: First Steps to Improve Professional Quality of Life and Address Burnout.
PMID 42575631 — quality of life, fibrosis, cystic fibrosis, thoracic diseases, burnout, psychological
Chest20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 5
N/A 1
Phase 1/Phase 2 1

By status:

Completed 7

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

LeadR Networks

Main global connection map